Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
Piyada Supasa, Daming Zhou, Wanwisa Dejnirattisai, et al.
Cell (2021) Vol. 184, Iss. 8, pp. 2201-2211.e7
Open Access | Times Cited: 513

Showing 1-25 of 513 citing articles:

The biological and clinical significance of emerging SARS-CoV-2 variants
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 976
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Wanwisa Dejnirattisai, Jiandong Huo, Daming Zhou, et al.
Cell (2022) Vol. 185, Iss. 3, pp. 467-484.e15
Open Access | Times Cited: 921
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Thibault Fiolet, Yousra Kherabi, Conor-James MacDonald, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 202-221
Open Access | Times Cited: 820
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults
Nawal Al Kaabi, Yuntao Zhang, Shengli Xia, et al.
JAMA (2021)
Open Access | Times Cited: 759
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Chang Liu, Helen M. Ginn, Wanwisa Dejnirattisai, et al.
Cell (2021) Vol. 184, Iss. 16, pp. 4220-4236.e13
Open Access | Times Cited: 708
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
Aekkachai Tuekprakhon, Rungtiwa Nutalai, Aiste Dijokaite-Guraliuc, et al.
Cell (2022) Vol. 185, Iss. 14, pp. 2422-2433.e13
Open Access | Times Cited: 668
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
Katherine R. W. Emary, Tanya Golubchik, Parvinder K. Aley, et al.
The Lancet (2021) Vol. 397, Iss. 10282, pp. 1351-1362
Open Access | Times Cited: 624
Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals
Alison Tarke, John Sidney, Nils Methot, et al.
Cell Reports Medicine (2021) Vol. 2, Iss. 7, pp. 100355-100355
Open Access | Times Cited: 618
Antibody evasion by the P.1 strain of SARS-CoV-2
Wanwisa Dejnirattisai, Daming Zhou, Piyada Supasa, et al.
Cell (2021) Vol. 184, Iss. 11, pp. 2939-2954.e9
Open Access | Times Cited: 616
SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity
Chihiro Motozono, Mako Toyoda, Jiří Zahradník, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 7, pp. 1124-1136.e11
Open Access | Times Cited: 518
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2021) Vol. 397, Iss. 10289, pp. 2049-2059
Open Access | Times Cited: 471
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
Joana Barros‐Martins, Swantje I. Hammerschmidt, Anne Cossmann, et al.
Nature Medicine (2021) Vol. 27, Iss. 9, pp. 1525-1529
Open Access | Times Cited: 412
Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
Catherine J. Reynolds, Corinna Pade, Joseph M. Gibbons, et al.
Science (2021) Vol. 372, Iss. 6549, pp. 1418-1423
Open Access | Times Cited: 351
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
Deborah Cromer, Megan Steain, Arnold Reynaldi, et al.
The Lancet Microbe (2021) Vol. 3, Iss. 1, pp. e52-e61
Open Access | Times Cited: 340
Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics
Michael I. Barton, Stuart A. MacGowan, Mikhail A. Kutuzov, et al.
eLife (2021) Vol. 10
Open Access | Times Cited: 333
COVID-19 vaccine development: milestones, lessons and prospects
Maochen Li, Han Wang, Lili Tian, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 331
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
Rebecca P. Payne, Stephanie Longet, James Austin, et al.
Cell (2021) Vol. 184, Iss. 23, pp. 5699-5714.e11
Open Access | Times Cited: 314
Inflammasome activation at the crux of severe COVID-19
Setu M. Vora, Judy Lieberman, Hao Wu
Nature reviews. Immunology (2021) Vol. 21, Iss. 11, pp. 694-703
Open Access | Times Cited: 288
An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies
Yafei Liu, Wai Tuck Soh, Jun-ichi Kishikawa, et al.
Cell (2021) Vol. 184, Iss. 13, pp. 3452-3466.e18
Open Access | Times Cited: 258
Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis
Baoqi Zeng, Le Gao, Qingxin Zhou, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 234
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
John Frater, Katie Ewer, Ane Ogbe, et al.
The Lancet HIV (2021) Vol. 8, Iss. 8, pp. e474-e485
Open Access | Times Cited: 233
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
Markus Hoffmann, Heike Hofmann-Winkler, Nadine Krüger, et al.
Cell Reports (2021) Vol. 36, Iss. 3, pp. 109415-109415
Open Access | Times Cited: 232
A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics
Lauren Forchette, William Sebastian, Tuoen Liu
Current Medical Science (2021) Vol. 41, Iss. 6, pp. 1037-1051
Open Access | Times Cited: 224
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines
Jia Wei, Koen B. Pouwels, Nicole Stoesser, et al.
Nature Medicine (2022) Vol. 28, Iss. 5, pp. 1072-1082
Open Access | Times Cited: 216
SARS-COV-2 Variants: Differences and Potential of Immune Evasion
Sandro Massao Hirabara, Tamires Duarte Afonso Serdan, Renata Gorjão, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 11
Open Access | Times Cited: 206
Page 1 - Next Page

Scroll to top